Oxazolidinone
A class of synthetic antibiotics used to treat infections caused by Gram-positive bacteria
Oxazolidinones are a class of synthetic antibiotics that are particularly effective against Gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). They are characterized by a unique mechanism of action that involves the inhibition of bacterial protein synthesis.
History[edit | edit source]
The development of oxazolidinones began in the 1980s, with the first clinically approved drug, Linezolid, being introduced in 2000. This marked a significant advancement in the treatment of infections caused by resistant Gram-positive bacteria.
Mechanism of Action[edit | edit source]
Oxazolidinones inhibit bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome. This action prevents the formation of the initiation complex necessary for translation, thereby halting protein synthesis and bacterial growth. Unlike many other antibiotics, oxazolidinones do not affect the 30S subunit, which contributes to their unique mechanism.
Pharmacokinetics[edit | edit source]
Oxazolidinones are well absorbed orally, with bioavailability often exceeding 90%. They are also available in intravenous formulations. The drugs are metabolized in the liver and excreted primarily in the urine. The half-life of oxazolidinones allows for twice-daily dosing, which is convenient for patients.
Clinical Uses[edit | edit source]
Oxazolidinones are primarily used to treat infections caused by Gram-positive bacteria, including:
Resistance[edit | edit source]
Resistance to oxazolidinones is relatively rare but has been documented. It typically arises from mutations in the 23S rRNA of the bacterial ribosome, which reduces the binding affinity of the drug. Resistance can also occur through the acquisition of the cfr gene, which methylates the ribosomal RNA and prevents drug binding.
Side Effects[edit | edit source]
Common side effects of oxazolidinones include:
- Gastrointestinal disturbances (nausea, diarrhea)
- Headache
- Thrombocytopenia (low platelet count)
Long-term use can lead to more serious side effects such as:
- Peripheral neuropathy
- Optic neuropathy
- Lactic acidosis
Examples of Oxazolidinones[edit | edit source]
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD